C

    Cytosorbents Crp (CTSO)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $0.34
    +0.01 (+1.61%)

    Market Cap: $21.09M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    53%(21/40)
    Avg Surprise
    -16.70%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.04
    Range$-0.05 - $-0.04
    2 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate Drift
    90d ago$-0.03+33.3%
    60d ago$-0.04+22.2%
    30d ago$-0.04+22.2%
    7d ago$-0.04+11.1%
    Current$-0.04
    Revenue Consensus
    $10M
    Range$10M - $10M
    2 analysts
    Dec 31, 2026
    EPS Consensus$-0.08
    Range$-0.08 - $-0.08
    2 analysts
    Revenue Consensus
    $10M
    Range$10M - $11M
    2 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.08---
    Sep 26EST
    		-$-0.04---
    Jun 26
    		$-0.07$-0.05-40.00%Miss-40.0%
    Mar 26
    		$-0.08$-0.05-60.00%Miss-300.0%
    Dec 25
    		$-0.09$-0.04-104.08%Miss+35.7%
    Sep 25
    		$-0.05$-0.05+0.00%Beat+37.5%
    Jun 25
    		$-0.05$-0.07+28.57%Beat+37.5%
    Mar 25
    		$-0.02N/A+71.43%Beat+83.3%
    Dec 24
    		$-0.14$-0.05-162.66%Miss-7.7%
    Sep 24
    		$-0.08$-0.06-33.33%Miss+61.9%
    Jun 24
    		$-0.08$-0.10+20.00%Beat+42.9%
    Mar 24
    		$-0.12$-0.12+0.00%Beat+29.4%
    Dec 23
    		$-0.13$-0.14+7.14%Beat-1200.0%
    Sep 23
    		$-0.21$-0.12-75.00%Miss+25.0%
    Jun 23
    		$-0.14$-0.14+0.00%Beat+44.0%
    Mar 23
    		$-0.17$-0.13-30.77%Miss+19.0%
    Dec 22
    		$-0.01N/A+93.33%Beat+95.2%
    Sep 22
    		$-0.28$-0.16-75.00%Miss-86.7%
    Jun 22
    		$-0.25$-0.12-108.33%Miss-127.3%
    Mar 22
    		$-0.21$-0.14-50.00%Miss-110.0%
    Dec 21
    		$-0.21$-0.13-61.54%Miss-2000.0%
    Sep 21
    		$-0.15$-0.12-25.00%Miss-650.0%
    Jun 21
    		$-0.11$-0.05-120.00%Miss-37.5%
    Mar 21
    		$-0.10$-0.05-100.00%Miss+0.0%
    Dec 20
    		$-0.01N/A+75.00%Beat+91.7%
    Sep 20
    		$-0.02N/A+77.78%Beat+90.5%
    Jun 20
    		$-0.08$-0.09+11.11%Beat+27.3%
    Mar 20
    		$-0.10$-0.15+33.33%Beat+33.3%
    Dec 19
    		$-0.12$-0.16+25.00%Beat+29.4%
    Sep 19
    		$-0.21$-0.14-50.00%Miss-110.0%
    Jun 19
    		$-0.11$-0.14+21.43%Beat+42.1%
    Mar 19
    		$-0.15$-0.18+16.67%Beat-50.0%
    Dec 18
    		$-0.17$-0.13-30.77%Miss-54.5%
    Sep 18
    		$-0.10$-0.14+28.57%Beat-42.9%
    Jun 18
    		$-0.19$-0.13-46.15%Miss-375.0%
    Mar 18
    		$-0.10$-0.13+23.08%Beat-100.0%
    Dec 17
    		$-0.11$-0.09-22.22%Miss+35.3%
    Sep 17
    		$-0.07$-0.07+0.00%Beat+36.4%
    Jun 17
    		$-0.04$-0.06+33.33%Beat-
    Mar 17
    		$-0.05$-0.10+50.00%Beat-
    Dec 16
    		$-0.17$-0.09-88.89%Miss-
    Sep 16
    		$-0.11$-0.11+0.00%Beat-

    Key Metrics

    Valuation
    P/E Ratio-1.18EV/EBITDA-1.92x
    Price/FCF-2.30xFCF Yield-43.41%
    Profitability
    Profit Margin-48.90%Operating Margin-24.60%
    ROE-336.20%ROIC-91.96%
    Financial Health
    Debt/Equity-22.96xInterest Coverage-2.73x
    Current Ratio0.66xQuick Ratio0.50x
    Trading Statistics
    Beta1.35Avg Volume101.11K
    52-Week High$1.0452-Week Low$0.30

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$0.35
    SMA 20$0.36
    SMA 50$0.38
    SMA 200$0.57
    EMA 10$0.35
    EMA 20$0.36
    EMA 50$0.39
    EMA 200$0.56

    MACD

    Line: -0.01Signal: -0.01Hist: -0.00

    ADX

    ADX: 19.6+DI: 8.5-DI: 19.4

    Aroon & PSAR

    Aroon Up60.0
    Aroon Down72.0
    PSAR$0.31

    Bollinger Bands

    Upper Band$0.40
    Lower Band$0.32
    %B Position2297%(Upper)
    Band Width0.24

    RSI (14-Day)

    Neutral
    44.3

    Momentum Oscillators

    Stoch %K39.0
    Stoch %D45.4
    Williams %R-59.0
    ROC (10d)-9.6%
    Momentum-0.04
    CCI (20d)-177.2
    MFI (14d)49.6

    Volatility Measures

    ATR (14d)$0.04(11.1%)
    StdDev (20d)0.02
    Hist Vol106.8%(High)

    Volume Flow

    VWAP$0.33
    OBV3.2M
    AD Line-3.7M
    CMF (20d)-0.175

    Volume Metrics

    Avg Vol (20d)101.6K
    Vol Ratio1.1x
    VWMA (20d)$0.36

    Pivot Points

    R3$0.42
    R2$0.40
    R1$0.37
    Pivot Point$0.34
    S1$0.31
    S2$0.29
    S3$0.26

    Advanced Oscillators

    TSI-9.08
    Ultimate Osc44.5
    KST-57.81

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$9.63M$8.86M$9.23M$9.48M$9.62M$8.73M$9.15M$8.61M$8.84M$8.99M$3.40M$8.81M
    Cost of Revenue$2.58M$2.73M$2.43M$2.82M$2.80M$2.52M$2.90M$3.36M$2.34M$2.12M$-1,468,705$3.20M
    Gross Profit$7.05M$6.13M$6.80M$6.67M$6.81M$6.21M$6.25M$5.26M$6.50M$6.87M$4.87M$5.61M
    Operating Expenses$9.69M$9.17M$11.19M$9.53M$10.43M$10.10M$9.65M$10.09M$10.07M$11.53M$15.02M$12.96M
    R&D$1.45M$1.02M$1.24M$918,000$1.26M$1.66M$2.02M$1.83M$1.52M$2.25M$3.96M$3.75M
    SG&A$7.96M$8.15M$9.44M$8.61M$9.17M$8.43M$7.63M$8.26M$8.55M$9.28M$11.06M$9.21M
    Operating Income$-2,638,000$-3,044,000$-4,384,792$-2,862,000$-3,615,000$-3,888,000$-3,395,632$-4,830,000$-3,570,000$-4,656,368$-10,147,589$-7,350,198
    Interest Income$-868,000$-857,000$-745,866$-645,000$-616,000$-605,000$-624,347$-588,000$-180,000$-6,653$-52,230$-33,670
    Interest Expense$1.78M$2.08M$1.11M$709,000$0$0$5.86M$0$724,000$1.43M$0$1.84M
    Income Before Tax$-4,417,000$-5,129,000$-5,496,642$-3,571,000$1.95M$-1,479,000$-9,259,289$-2,768,000$-4,294,000$-6,088,711$-7,388,012$-9,193,520
    Income Tax Expense$0$0$0$-401,000$0$0$0$0$0$0$0$0
    Net Income$-4,417,000$-5,129,000$-5,496,642$-3,170,000$1.95M$-1,479,000$-7,568,289$-2,768,000$-4,294,000$-6,088,711$-6,574,273$-9,193,520
    EBITDA$-2,891,000$-3,605,000$-4,116,776$-2,335,000$3.19M$-279,000$-8,018,942$-1,561,000$-3,667,213$-5,638,845$-6,546,478$-8,697,202
    EBIT$-3,549,000$-4,272,000$-4,750,776$-2,926,000$2.56M$-874,000$-8,634,942$-2,180,000$-4,114,000$-6,082,058$-7,335,782$-9,159,850
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about CTSO

    News

    CytoSorbents (CTSO) wins approval for reverse split and director slate at 2026 meeting

    CytoSorbents Corporation (CTSO) held its 2026 Annual Meeting, where shareholders approved a reverse stock split plan with a ratio between 1-for-5 and 1-for-20, to be implemented at the Board's discretion within one year. Additionally, five directors were elected, executive officer compensation was approved on a non-binding advisory basis, and WithumSmith+Brown, PC was ratified as the independent registered public accounting firm for 2026. The meeting achieved a quorum with 42,487,327 shares represented out of 62,842,748 outstanding common shares.

    Stock Titan•8/14/26•
    Neutral

    Cytosorbents (CTSO) Q2 2026 Earnings Call Transcript

    Cytosorbents (CTSO) reported stable Q2 2026 revenue of $9.6 million, with gross margins improving to 73% and operating cash burn significantly reduced to $200,000, excluding restructuring costs. The company is pursuing U.S. market approval for its DrugSorb-ATR device for both ticagrelor and DOAC removal, with planned FDA meetings and ongoing real-world evidence collection. Additionally, Cytosorbents highlighted the strategic value of its HemoDefend-BGA technology for universal plasma, seeking non-dilutive government funding for its clinical development.

    The Globe and Mail•8/14/26•
    Somewhat-Bullish

    Cytosorbents Corp (CTSO) Earnings Forecast: Future EPS & Revenue Growth Estimates

    This article provides an earnings forecast for Cytosorbents Corp (CTSO), detailing its current earnings forecast score, average price target from analysts, and expected revenue and EPS for upcoming quarters. One analyst currently rates the stock as "Hold" with a significant upside potential to the target price. The company's expected revenue for the next quarter is $9.78 million, and its EPS is projected at -$0.04.

    TradingKey•8/10/26•
    Somewhat-Bullish

    Q2 2026 Cytosorbents Corp Earnings Call Transcript

    This document contains the Q2 2026 earnings call transcript for Cytosorbents Corp (NAS:CTSO), held on August 6, 2026. Key points from the call indicate a significant reduction in operating cash burn, improved gross margins, and growth in the distributor network revenue. However, challenges include missed efficacy endpoints in the STAR-T trial, ongoing revenue difficulties in Germany, and a low cash position requiring further financing.

    GuruFocus•8/9/26•
    Somewhat-Bearish

    Cytosorbents Corp (CTSO) Stock News Today

    This article provides recent news and financial updates for Cytosorbents Corp (CTSO). The company's stock experienced a 9.68% decline. The latest earnings report indicates that CytoSorbents' Q2 2026 earnings showed improved margins despite flat revenue.

    TradingKey•8/7/26•
    Somewhat-Bearish

    Frequently Asked Questions About CTSO

    Does CTSO pay dividends?
    Cytosorbents Crp (CTSO) does not currently pay a regular dividend.
    What is CTSO's market cap?
    Cytosorbents Crp (CTSO) has a market capitalization of $21.09M with a current stock price of $0.34.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In